LB Pharmaceuticals (LBRX) Stifel 2026 Virtual CNS Forum summary

Key clinical milestones and pipeline updates

• Phase 3 schizophrenia data expected in the second half of 2027, Phase 2 bipolar depression data in Q1 2028, and adjunctive MDD data in the first half of 2029, all for late-stage asset LB-102.

• Phase 2 schizophrenia trial showed robust efficacy with effect sizes between 0.5 and 0.6, supporting confidence for Phase 3.

• Phase 3 trial will use two doses (50 and 100 mg), extend duration to 6 weeks, and implement enhanced risk mitigation strategies to manage placebo rates.

• Bipolar depression and MDD trials will use fixed flexible dose designs to optimize efficacy and safety, with doses aligned to receptor occupancy data from amisulpride.

• Adjunctive MDD trial will be conducted in both Europe and the U.S. to ensure high-quality site selection.

Differentiation and competitive positioning

• LB-102 aims for competitive efficacy across schizophrenia, bipolar depression, and MDD, with potential class-leading safety and tolerability.

• Rapid onset of action and no titration required, differentiating from competitors like Uzedy.

• Low rates of extrapyramidal symptoms (EPS) and negligible sedation observed in Phase 2, comparing favorably to Caplyta and Vraylar.

• Opportunity to address residual symptoms such as cognitive impairment and anhedonia, which persist across all targeted indications.

• First benzamide of its class to be available in the U.S., potentially filling an unmet need recognized by physicians.

Risk mitigation and trial execution

• Extensive measures to minimize placebo response, including use of central raters, exclusion of professional patients, and careful selection of rating scales.

• Consistent engagement with clinical sites and CROs, leveraging overlap and established relationships from Phase 2 to Phase 3.

• SAFER criteria used in both bipolar and MDD trials to ensure accurate patient inclusion, though this may increase screen failure rates and lengthen enrollment.

• Dosing strategies for bipolar and MDD informed by receptor occupancy data and clinical experience with amisulpride.